Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Treasury Shares (2021 - 2026)

Enliven Therapeutics has reported Treasury Shares over the past 6 years, most recently at $323008.0 for Q1 2026.

  • Quarterly results put Treasury Shares at $323008.0 for Q1 2026, up 233.72% from a year ago — trailing twelve months through Mar 2026 was $323008.0 (up 233.72% YoY), and the annual figure for FY2025 was $76973.0, up 1.09%.
  • Treasury Shares reached $323008.0 in Q1 2026 per ELVN's latest filing, up from $76973.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $425289.0 in Q1 2022 and bottomed at $16424.0 in Q3 2023.
  • Median Treasury Shares over the past 5 years was $91251.0 (2024), compared with a mean of $129082.6.
  • The largest annual shift saw Treasury Shares plummeted 92.31% in 2023 before it surged 462.09% in 2024.
  • Over 5 years, Treasury Shares stood at $213443.0 in 2022, then crashed by 63.22% to $78505.0 in 2023, then decreased by 3.01% to $76145.0 in 2024, then grew by 1.09% to $76973.0 in 2025, then skyrocketed by 319.64% to $323008.0 in 2026.
  • Business Quant data shows Treasury Shares for ELVN at $323008.0 in Q1 2026, $76973.0 in Q4 2025, and $83577.0 in Q3 2025.